Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

@article{Kumar2009ManagementON,
  title={Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.},
  author={Shaji K Kumar and Joseph Mikhael and Francis K Buadi and David Dingli and Angela Dispenzieri and Rafael Le{\~a}o da Fonseca and Morie A Gertz and Philip R. Greipp and Suzanne R. Hayman and Robert A Kyle and Martha Q. Lacy and John A. Lust and Craig B. Reeder and Vivek Roy and Stephen Russell and Kristen E Detweiler Short and Alexander Stewart and Thomas E Witzig and Steven R. Zeldenrust and Robert J. Dalton and S Vincent Rajkumar and P Leif Bergsagel},
  journal={Mayo Clinic proceedings},
  year={2009},
  volume={84 12},
  pages={1095-110}
}
Multiple myeloma is a malignant plasma cell neoplasm that affects more than 20,000 people each year and is the second most common hematologic malignancy. It is part of a spectrum of monoclonal plasma cell disorders, many of which do not require active therapy. During the past decade, considerable progress has been made in our understanding of the disease process and factors that influence outcome, along with development of new drugs that are highly effective in controlling the disease and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 179 extracted citations

Similar Papers

Loading similar papers…